Recursion Stock Down Despite Meeting Goal in Brain Disease Study [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
and efficacy of its lead candidate, REC-994, an orally bioavailable, superoxide scavenger small molecule, for symptomatic cerebral cavernous malformation (CCM) patients. Recursion's SYCAMORE Study Meets Primary Goal but Efficacy Lags Recursion reported that its phase II SYCAMORE study met the primary endpoint of safety and tolerability in CCM patients treated with REC-994. However, the results lacked significant efficacy as treatment with placebo and both 200mg and 400mg doses of REC-994 demonstrated a similar adverse event profile after 12 months of treatment. Additionally, MRI-based secondary efficacy endpoints indicated a tendency for reduced lesion volume and hemosiderin ring size in patients receiving the 400mg dose of the candidate compared with those on placebo. However, no improvements were reported by patients or doctors at the 12-month mark. Detailed results from the SYCAMORE study will be presented at an upcoming medical conference. Recursion expects to meet with th
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock [Yahoo! Finance]Yahoo! Finance
- Recursion: Path Forward For REC-994 Remains Despite Mixed Response [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its price target lowered by analysts at Leerink Partners from $9.00 to $8.00. They now have a "market perform" rating on the stock.MarketBeat
RXRX
Earnings
- 8/8/24 - Miss
RXRX
Sec Filings
- 9/26/24 - Form 144
- 9/19/24 - Form 4
- 9/19/24 - Form DEFA14A
- RXRX's page on the SEC website